Connor, Clark & Lunn Investment Management (CC&L)
EBS icon

Connor, Clark & Lunn Investment Management (CC&L)’s Emergent Biosolutions EBS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
353,983
-294,394
-45% -$2.46M 0.01% 886
2026
Q1 		$5.38M Sell
648,377
-129,622
-17% -$1.34M 0.01% 666
2025
Q4 		$9.62M Sell
777,999
-354,306
-31% -$3.8M 0.03% 471
2025
Q3 		$9.99M Buy
1,132,305
+145,632
+15% +$1.13M 0.03% 412
2025
Q2 		$6.29M Buy
986,673
+55,046
+6% +$315K 0.02% 516
2025
Q1 		$4.53M Buy
931,627
+29,295
+3% +$242K 0.02% 525
2024
Q4 		$8.63M Buy
902,332
+69,157
+8% +$635K 0.04% 360
2024
Q3 		$6.96M Sell
833,175
-10,213
-1% -$92.8K 0.03% 364
2024
Q2 		$5.75M Buy
843,388
+137,153
+19% +$590K 0.02% 397
2024
Q1 		$1.79M Buy
706,235
+495,781
+236% +$1.12M 0.01% 704
2023
Q4 		$505K Buy
210,454
+920
+0.4% +$2.16K ﹤0.01% 1045
2023
Q3 		$712K Buy
+209,534
New +$1.16M ﹤0.01% 929
2023
Q2 		– Sell
-45,855
Closed -$475K – 1366
2023
Q1 		$475K Buy
+45,855
New +$554K ﹤0.01% 898
2020
Q4 		– Sell
-39,350
Closed -$4.07M – 934
2020
Q3 		$4.07M Buy
39,350
+16,929
+76% +$1.82M 0.03% 344
2020
Q2 		$1.77M Buy
+22,421
New +$1.67M 0.01% 481
2016
Q1 		– Sell
-50,400
Closed -$2.02M – 849
2015
Q4 		$2.02M Buy
50,400
+9,900
+24% +$345K 0.02% 338
2015
Q3 		$1.15M Buy
40,500
+34,400
+564% +$1.13M 0.01% 377
2015
Q2 		$201K Buy
+6,100
New +$189K ﹤0.01% 562
2014
Q2 		– Sell
-54,011
Closed -$1.51M – 556
2014
Q1 		$1.51M Buy
54,011
+23,900
+79% +$604K 0.01% 314
2013
Q4 		$736K Sell
30,111
-700
-2% -$14.6K 0.01% 427
2013
Q3 		$603K Buy
30,811
+5,711
+23% +$102K 0.01% 329
2013
Q2 		$382K Buy
+25,100
New +$363K ﹤0.01% 392

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EBS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Emergent Biosolutions (EBS) stake by 45% in Q2 2026, selling an estimated $2.46M and leaving 353,983 shares worth $2.97M. The position accounts for 0.01% of the portfolio, ranked #886.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EBS in Q2 2013 and has held it in 22 quarters since. The position peaked at $9.99M in Q3 2025. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 353,983 shares of Emergent Biosolutions worth $2.97M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 294,394 Emergent Biosolutions shares in Q2 2026, an estimated $2.46M.
  • Emergent Biosolutions made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #886 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 22 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Emergent Biosolutions position peaked at $9.99M in Q3 2025.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.